• This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE helps you survive cancer with a strong heart
  • Home
  • The Project
    Background
    The Resilience Project

    The RESILIENCE project develop a novel healthcare intervention (Remote Ischemic Conditioning, RIC) aimed at reducing the prevalence of chronic heart failure in cancer survivors. 

    More...
    The Challenge
    Reduce the Heart Failure in Cancer Survivors
    According to the WHO, the incidence of cancer is expected to rise by about 70% over the next 20 years.  Half of those diagnosed with cancer will survive for at least a decade, and this survival rate is expected to increase significantly in the future.
    More...
    The Therapy
    Remote Ischemic Conditioning

    Remote ischemic conditioning (RIC) is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury.

    More...
    Partners
    Multidisciplinary consortium
    We count on a multidisciplinary consortium, where different stakeholders of this process are part of the study, from scientists to industry, and from healthcare providers (physicians and nurses) to patients.
    More...
  • Cardiac Magnetic Resonance
    Cardiac Magnetic Resonance

    Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.

    More...
    Vulnerable Heart
    Heart Failure
    Healthy Heart
  • Clinical Trial
    Clinical Trial Synopsis

    Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.

    More...
  • For patients
    Videos
    closeup-of-support-hands
    More...
    Contact Form
    imgContactForm
    More...
  • Dissemination
    News
    Join us at the European Heart House in Nice for the RESILIENCE multi-stakeholder event: Survive cancer with a strong heart
    September 14 2023
    Science and Innovation Week
    September 11 2023
    RESILIENCE participates in the European Researchers Night in Madrid
    September 8 2023
    RESILIENCE broadens the spectrum of patients who may benefit from entering the trial
    August 14 2023
    Initial visit at the San Carlos Clinical Hospital
    June 16 2023
    More...
    Publications
    Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable
    July 14 2023
    Remote ischaemic conditioning: defining critical criteria for success—report from the 11th Hatter Cardiovascular Workshop
    August 24 2022
    The Quest for an Early Marker of<br>Anthracycline-Induced Cardiotoxicity
    February 21 2022
    Coronary microcirculation damage in anthracycline cardiotoxicity
    December 23 2021
    Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning?
    December 13 2021
    More...
  • Blog
Twitter Youtube Facebook Linkedin Instagram

Cardiale magnetische resonantie

Cardiale magnetische resonantie is een techniek zonder straling, die wordt beschouwd als de gouden standaard voor de evaluatie van hartanatomie, functie en zelfs weefselsamenstelling.

De RESILIENCE-studie zal Cardiale Magnetic Resonance (CMR) gebruiken als de belangrijkste uitkomstmaatmethodologie, en patiënten die aan de studie deelnemen, zullen gedurende de duur van de studie drie scans ondergaan. Door antracycline geïnduceerde hartschade (AIC) zal worden gediagnosticeerd op basis van veranderingen in de systolische functie van de linker ventrikel, zoals geëvalueerd door CMR.

Door gebruik te maken van de grote populatie die is gerekruteerd in de RESILIENCE-studie in heel Europa, zal een nieuwe CMR-methodologie worden gevalideerd die vroege AIC kan identificeren. De nieuwe methodologie is gebaseerd op multiparametrische CMR-beeldvorming, voornamelijk T2-mapping. In experimentele modellen is T2-mapping de vroegste parameter die in het AIC-proces is gewijzigd. Patiënten die deelnemen aan RESILIENCE zullen een uitgebreid CMR-onderzoek met contrastmiddel ondergaan, inclusief hartanatomie, functie, technieken voor beoordeling van de myocardiale belasting (“fast-strain-encoded-SENC”, tagging en functie-tracking), kwantitatieve perfusie en T1/T2-mapping .

Cardiale magnetische resonantie in RESILIENCE
Echte magnetische resonantieapparatuur (bron: National Center for Cardiovascular Research (CNIC))

Ondanks dat CMR universeel wordt erkend als de gouden standaardtechniek voor de evaluatie van het hart, wordt het niet universeel gebruikt. Een van de belangrijkste redenen hiervoor is dat beeldacquisitie lang duurt (45 tot 60 min voor een uitgebreid protocol). Deze lange duur resulteert in een lage beschikbaarheid van de apparatuur in de ziekenhuizen en ook in de belasting van de patiënt. Leden van het RESILIENCE-consortium hebben een revolutionaire CMR-techniek ontwikkeld die de scantijd enorm kan verkorten. Deze nieuwe 3D CMR-methodologie waarbij de patient éénkeer zijn of haar adem moet inhouden heet Enhance SENSE door Static Outer Volume Subtraction (ESSOS). Deze nieuwe methodologie kan een revolutie teweegbrengen op het gebied van CMR en de toegang van patiënten tot deze techniek vergroten. Bovendien zal deze techniek de belasting voor de patiënt verminderen, iets wat zeer relevant is voor kwetsbare populaties, zoals ouderen, kinderen. Het RESILIENCE-project zal deze nieuwe methodologie valideren (in vergelijking met de momenteel gebruikte).

Resilience

Cardiac Magnetic Resonance

  • Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

Clinical Trial Synopsis

  • Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning.

For patients

Legals

Follow Us

Twitter Youtube Facebook Linkedin Instagram
  • This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118

RESILIENCE is a CNIC project with a multidisciplinary consortium | All Rights Reserved 2022

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions